Cargando…

Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report

We herein report a non-smoking 81-year-old man with advanced synchronous multiple primary lung cancers (SMPLC), containing squamous cell carcinoma with strong programmed death-ligand 1 expression in the middle lobe and adenocarcinoma with epidermal growth factor receptor (EGFR) exon 19 deletion in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokuyasu, Hirokazu, Horie, Mika, Ishikawa, Soichiro, Sakai, Hiromitsu, Miura, Hiroshi, Yamasaki, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921201/ https://www.ncbi.nlm.nih.gov/pubmed/31886125 http://dx.doi.org/10.1016/j.rmcr.2019.100976

Ejemplares similares

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
por: Ikeuchi, Tomoyuki, et al.
Publicado: (2019)

Combination treatment with antibiotics and surgical lung resection for Mycobacterium abscessus pulmonary infection in a breast cancer patient
por: Tokuyasu, Hirokazu, et al.
Publicado: (2021)

Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma
por: Tokuyasu, Hirokazu, et al.
Publicado: (2019)

MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
por: Ju, Lixia, et al.
Publicado: (2017)

Granulomatosis with polyangiitis diagnosed during the treatment of otitis media with prednisolone in a patient with anti-neutrophil cytoplasmic antibody-associated vasculitis: A case report
por: Tokuyasu, Hirokazu, et al.
Publicado: (2022)

3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
por: Liu, Guixue, et al.
Publicado: (2020)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Comparison of pathological findings and accumulation of fluorin-18 fluorodeoxyglucose on positron emission tomography/computed tomography: A case of relapsing polychondritis
por: Tokuyasu, Hirokazu, et al.
Publicado: (2023)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
por: Chen, Shubin, et al.
Publicado: (2023)

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma
por: Dahse, R, et al.
Publicado: (2008)

Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
por: Tamirat, Mahlet Z., et al.
Publicado: (2019)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Detection of internal exon deletion with exon Del
por: Guo, Yan, et al.
Publicado: (2014)

Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
por: Debbabi, Inès, et al.
Publicado: (2023)

Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion
por: Weiss, Glen J., et al.
Publicado: (2013)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Fluorometric Detection of Low-Abundance EGFR Exon 19 Deletion Mutation Using Tandem Gene Amplification
por: Kim, Dong-Min, et al.
Publicado: (2020)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
por: Yu, Jiang-Yong, et al.
Publicado: (2016)

Exonic deletions in GALC are frequent in Japanese globoid-cell leukodystrophy patients
por: Irahara-Miyana, Kaori, et al.
Publicado: (2018)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs
por: Xu, Chun-wei, et al.
Publicado: (2020)

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer
por: Brown, Benjamin P., et al.
Publicado: (2022)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
por: Jing, Wei, et al.
Publicado: (2020)

Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
por: Costa, D B, et al.
Publicado: (2007)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
por: Wang, Taishu, et al.
Publicado: (2018)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion
por: Zu, Yunfen, et al.
Publicado: (2021)

Score for lung adenocarcinoma in China with EGFR mutation of exon 19: Combination of clinical and radiological characteristics analysis
por: Shi, Zhang, et al.
Publicado: (2018)

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Wang, Yurong, et al.
Publicado: (2021)

Classifying Included and Excluded Exons in Exon Skipping Event Using Histone Modifications
por: Chen, Wei, et al.
Publicado: (2018)

Analysis of TMIE gene mutations including the first large deletion of exon 1 with autosomal recessive non-syndromic deafness
por: Rayat, Sima, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vvqolcvds2lvv9hoj1dhqo5kkc